Patents Assigned to Signum Biosciences, Inc.
  • Patent number: 11802107
    Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: October 31, 2023
    Assignee: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Eduardo Perez, Jason Healy, Jose Fernandez
  • Publication number: 20230174467
    Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Application
    Filed: December 5, 2022
    Publication date: June 8, 2023
    Applicant: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Eduardo Perez, Jason Healy, Jose Fernandez
  • Patent number: 11518738
    Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 6, 2022
    Assignee: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
  • Publication number: 20210261499
    Abstract: The present invention provides compounds useful in treating or preventing inflammation, acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Application
    Filed: March 12, 2021
    Publication date: August 26, 2021
    Applicant: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
  • Patent number: 10975023
    Abstract: The present invention provides compounds useful in treating or preventing inflammation acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 13, 2021
    Assignee: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
  • Patent number: 10912812
    Abstract: Method of preparing a botanical extract that includes contacting a raw botanical with a solvent having a dielectric constant ranging from about 2.3 to about 25 and allowing the mixture to reside for a sufficient time to obtain a crude extract; filtering out remaining raw botanical and evaporating the solvent from the crude extract under reduced pressure to obtain a dried crude extract; washing the dried crude extract with a polar solvent having a dielectric constant of no less than 30, heating the resulting mixture, and allowing to cool to ambient; collecting a filtrate from the above cooled mixture; washing the collected filtrate with a non-polar solvent having a dielectric constant of no more than 2.0; and filtering and drying the mixture to obtain the botanical extract.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: February 9, 2021
    Assignee: Signum Biosciences, Inc.
    Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
  • Publication number: 20200179319
    Abstract: Disclosed herein are pharmaceutical compositions, comprising a therapeutically effective amount of 4-((1-carboxy-2-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)ethyl)amino)-4-oxobutanoic acid, or a pharmaceutically acceptable salt thereof, and at least one protective agent, and uses thereof.
    Type: Application
    Filed: August 4, 2017
    Publication date: June 11, 2020
    Applicant: Signum Biosciences, Inc.
    Inventors: Thomas John Willi, John Frederick Lang, Laura Jean Weston
  • Patent number: 10583119
    Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 10, 2020
    Assignee: Signum Biosciences, Inc.
    Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
  • Publication number: 20200017438
    Abstract: The present invention provides compounds useful in treating or preventing inflammation acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Application
    Filed: January 12, 2018
    Publication date: January 16, 2020
    Applicant: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
  • Publication number: 20190336561
    Abstract: Compositions containing natural and botanical extracts for use in inhibiting one, two, or three of (a)-(c): (a) demethylation of PP2A by PME-1 methylesterase; (b) formation of free radicals and reactive oxygen species; and/or (c) inflammation. These compositions include an extract of one or more botanicals selected from the group consisting of: juniper berry fruit, schisandra fruit, strawberry fruit, avocado seeds, black raspberry seeds, blueberry seeds, celery seeds, cranberry seeds, fennel seeds, grape seeds, guarana seeds, red raspberry seeds, maca root, goldenseal root, turmeric root, magnolia bark, pygeum bark, red raspberry leaf, almond, cocoa powder, Echinacea angustifolia, prickly pear cactus and walnut.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 7, 2019
    Applicant: Signum Biosciences, Inc.
    Inventors: Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Eduardo Perez, Maxwell Stock, Jeffry Stock
  • Patent number: 10314817
    Abstract: EHT extract including a mixture of late eluting tryptamides and early eluting tryptamides in a weight ratio of at least about 7:1 late eluting tryptamides:early eluting tryptamides, wherein the EHT extract includes at least 30% eicosanoyl-5-hydroxytryptamide, based on the total weight of the tryptamides in the EHT extract.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: June 11, 2019
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry Stock, Maxwell Stock, Michael Voronkov, Jose Fernandez, Kristen Huber
  • Patent number: 10314802
    Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: June 11, 2019
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
  • Publication number: 20190167619
    Abstract: A pharmaceutical composition comprising (a) at least one protective agent selected from the group consisting of butylated hydroxyanisole, butylated hydroxytoluene, sodium metabisulfite, tert-butylhydroquinone, methylparaben, propylparaben, benzyl alcohol, poly(acrylic acid), hydroxyethyl cellulose, emulsifying wax, PEG-21 stearyl ether, PEG-2 stearyl ether, white petrolatum, myristyl lactate, diisopropyl adipate, cetyl alcohol, cyclomethicone, oleyl alcohol, cholesterol, and polyoxyethylene(4)lauryl ether; and (b) a therapeutically effective amount of an IPC Active Agent or a pharmaceutically acceptable salt or ester thereof.
    Type: Application
    Filed: August 8, 2017
    Publication date: June 6, 2019
    Applicant: SIGNUM BIOSCIENCES, INC.
    Inventors: Michael VORONKOV, Gareth WINCKLE
  • Patent number: 10117904
    Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: November 6, 2018
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry B. Stock, Maxwell Stock
  • Publication number: 20170368011
    Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
    Type: Application
    Filed: August 1, 2017
    Publication date: December 28, 2017
    Applicant: SIGNUM BIOSCIENCES, INC.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
  • Publication number: 20170266161
    Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.
    Type: Application
    Filed: November 8, 2016
    Publication date: September 21, 2017
    Applicant: Signum Biosciences, Inc.
    Inventors: SCOTT VAFAI, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
  • Patent number: 9744147
    Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 29, 2017
    Assignee: Signum Biosciences, Inc.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen, Jinglong Chen
  • Patent number: 9486441
    Abstract: The present invention provides compounds and/or compositions that modulate PP2A methylation and/or activity and methods for preparing the same, which are useful for modulating the demethylation of PP2A, modulating the methylation of PP2A and/or modulating the activity of PP2A.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: November 8, 2016
    Assignee: SIGNUM BIOSCIENCES, INC.
    Inventors: Scott Vafai, Michael Voronkov, Maxwell Stock, Jeffry B. Stock, Seung-Yub Lee, Zhu Li, Haoming Gu
  • Patent number: 9415026
    Abstract: Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: August 16, 2016
    Assignee: SIGNUM BIOSCIENCES, INC.
    Inventors: Jeffry B. Stock, Maxwell Stock
  • Patent number: 9376383
    Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: June 28, 2016
    Assignee: SIGNUM BIOSCIENCES, INC.
    Inventors: Jeffry B. Stock, Maxwell Stock, Keshava Rapole, Seung-Yub Lee, Michael Voronkov, Eduardo Perez, Joel Gordon, Shuyi Chen